Boston Family Office LLC Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Boston Family Office LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 83.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,342 shares of the company’s stock after buying an additional 4,258 shares during the period. Boston Family Office LLC’s holdings in Moderna were worth $624,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the second quarter valued at approximately $26,000. Family Firm Inc. purchased a new stake in shares of Moderna in the second quarter valued at approximately $33,000. Bank & Trust Co purchased a new stake in shares of Moderna in the second quarter valued at approximately $36,000. Hanseatic Management Services Inc. acquired a new position in Moderna in the second quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd lifted its holdings in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 2,930 shares of company stock worth $217,170 over the last quarter. 15.20% of the stock is currently owned by company insiders.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $43.66 on Tuesday. The firm’s 50 day moving average is $54.96 and its two-hundred day moving average is $93.71. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47. The firm has a market capitalization of $16.80 billion, a P/E ratio of -7.50 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter last year, the business earned ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Analysts anticipate that Moderna, Inc. will post -9.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on MRNA shares. Jefferies Financial Group decreased their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Leerink Partners decreased their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. TD Cowen decreased their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and decreased their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein initiated coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $84.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.